Earlier Detection of Cognitive Disorders with Marc Jones of Altoida
Aired On: September 16, 2025
Marc Jones, CEO of Altoida, joins our hosts to talk about their NeuroMarker platform and its potential to detect cognitive disorders like Alzheimer’s in earlier stages. Learn how earlier detection enables more effective treatment, and how Altoida is working to change the current standard of care for Alzheimer’s.
Add to Your Queue
Resources
More Episodes
The Current State of Medtech Startups with Alyssa Huffman & Ted Bird
January 14, 2025
Application Development for Older Adults with Jennifer Cain Birkmose
September 17, 2024
AI’s Role in Proactive Healthcare with Adityo Prakash
April 9, 2024
In this Episode
- 00:00 Introduction to Altoida and Neuromarker Platform
- 02:56 Understanding the Assessment Process
- 05:48 Comparison with Current Standard of Care
- 11:48 The Importance of Early Detection
- 17:29 Future of Cognitive Health Monitoring
- 23:16 Company Strategy and Future Direction
Quotes From This Episode
There’s published data that tells us that 90% of mild cognitive impairment, I’ll refer to that as MCI, 90% of those cases go undiagnosed. There are millions of people, and I’m just speaking in the US right now, walking around with mild cognitive impairment and they’re not being diagnosed.
Marc Jones
We need to be early, we need to be preclinical, we need to be before overt symptoms start to take over. Because again, the published data suggests that that’s where these treatments are most effective. Like any disease state, early detection matters.
Marc Jones
There’s a great brain health curve. Everyone as we get older, we’re gonna see it tail off in every aspect of our physiology. And one of those is brain function, but what we’re seeing is a much sharper curve. And so, if you ask me what is the mission of Altoida, it’s very simply to push the arc of that unhealthy brain as close to normative brain aging as possible.
Marc Jones
